Hideo Kunitoh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hideo Kunitoh has a total of 220 co-authors. Here are the top co-authors by number of shared publications:
- Shun-Ichi Watanabe
Department of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
2 shared publications - Adeline Seow
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System , Singapore
1 shared publication - Adonina Tardón
14Health Research Institute of Asturias (ISPA) and Faculty of Medicine, University Nebrija, Campus Berzosa, Madrid, Spain
1 shared publication Akiteru Goto
Department of Cellular and Organ Pathology, Graduate School of Medicine, Akita University , Akita
1 shared publicationAlan Dart Loon Sihoe
Gleneagles Hong Kong Hospital , Hong Kong
1 shared publication- Amy Hutchinson
Division of Cancer Epidemiology and Genetics, National Cancer Institute , Bethesda, MD
1 shared publication
Latest Publications
- 29 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
A randomized phase III study optimizing adjuvant osimertinib for resected EGFR -mutant stage II–III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01)
The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II–III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.
- 29 October 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
A randomized phase III study optimizing adjuvant osimertinib for resected EGFR -mutant stage II–III non-squamous non-small cell lung cancer: OASIS trial (JACTOP-01)
The OASIS trial [Japan Cancer Treatment Optimization group (JACTOP)-01] is a multicenter, randomized, open-label, phase III study optimizing adjuvant osimertinib therapy for patients with completely resected, epidermal growth factor receptor (EGFR)-mutated (exon 19 deletion or L858R) stage II–III non-squamous non-small cell lung cancer. Based on the ADAURA trial, the standard adjuvant dose of osimertinib is 80 mg/day, which often causes significant adverse events and financial toxicity. This trial evaluates the non-inferiority of a reduced dose of 40 mg/day of osimertinib compared to the standard 80 mg/day. A total of 420 patients will be randomized (1:1) to receive either osimertinib 80 or 40 mg/day orally for 3 years. The primary endpoint is disease-free survival. Secondary endpoints include overall survival, central nervous system disease-free survival, safety, and quality of life. If non-inferiority is confirmed, osimertinib 40 mg/day will establish a new optimal adjuvant strategy, improving patient quality of life and reducing medical economic burdens.
- 9 January 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (1) , 1-4
Message from the Editor-in-Chief
- 9 January 2026
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (1) , 1-4
Message from the Editor-in-Chief
- 1 October 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 231-249
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Background: Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods: PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results: The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions: Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.
- 1 October 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 118 (2) , 231-249
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers
Background: Lung adenocarcinoma in never-smokers is a major public health burden, especially among East Asian women. Polygenic risk scores (PRSs) are promising for risk stratification but are primarily developed in European-ancestry populations. We aimed to develop and validate single- and multi-ancestry PRSs for East Asian never-smokers to improve lung adenocarcinoma risk prediction. Methods: PRSs were developed using genome-wide association study summary statistics from East Asian (8002 cases; 20 782 controls) and European (2058 cases; 5575 controls) populations. Single-ancestry models included a PRS with 25 single nucleotide variants (PRS-25), PRS clumping and thresholding (CT), and LDpred2; multi-ancestry models included LDpred2 plus European PRS-128, PRS-CSx, and clumping and thresholding, super learning, empirical Bayes (CT-SLEB). Performance was evaluated in independent East Asian data from the Female Lung Cancer Consortium and externally validated in the Nanjing Lung Cancer Cohort. We assessed predictive accuracy via area under the curve operating procedure (AUC), with 10-year and (ages 30-80 years) absolute risks estimates. Results: The best multi-ancestry PRS, using East Asian and European data via CT-SLEB, outperformed the best East Asian-only (LDpred2; AUC = 0.629, 95% confidence interval [CI] = 0.618 to 0.641), achieving an AUC of 0.640 (95% CI = 0.629 to 0.653) and odds ratio of 1.71 (95% CI = 1.61 to 1.82) per standard deviation increase. Nanjing Lung Cancer Cohort validation confirmed robust performance (AUC = 0.649, 95% CI = 0.623 to 0.676). The top 20% PRS group had a 3.92-fold higher lung adenocarcinoma risk than the bottom 20%. Further, the top 5% PRS group reached a 6.69% lifetime absolute risk. Notably, this group reached the average population 10-year lung adenocarcinoma risk at age 50 years (0.42%) by age 41 years, 9 years earlier. Conclusions: Multi-ancestry PRS approaches enhance lung adenocarcinoma risk stratification in East Asian never-smokers, with consistent external validation, suggesting future clinical utility.